Phage Display Antibody Library
Novel Antibody Discovery Service
Discover cutting-edge Phage Display Antibody Library Services with us. Leveraging the power of phage display technology, we provide tailored solutions for discovering high-affinity antibodies to meet your unique requirements. Our high-quality Antibody libraries, enable comprehensive exploration of potential CDR variants, ensuring thorough hit identification.
Our team, equipped with molecular biology expertise and dedicated to innovation, is committed to delivering what you need. Accelerate your monoclonal antibody development program with GeNext Genomics’ phage display services, and receive your antibodies within just 2 months!
Phage Display Technology
Phage display is a selection technique that involves genetic engineering of bacteriophages and repeated antigen-based selection and propagation. It offers a promising alternative for antibody generation outside the immune system, eliminating the need for laboratory animals. Antibody libraries are crafted from genomic information encoding antibody variable domains, sourced from B cells of either native or immune donors.
Finding a high-affinity, target-specific antibody shouldn’t take years. With GNG’s antibody discovery services, powered by our proprietary HIND® phage display library, you get a proven, animal-free route to potent binders, delivered within as little as 2 months.
Our phage display antibody discovery platform draws from a high-diversity gene pool spanning healthy donors and disease backgrounds, constructing both naïve and immune library phage display formats. Whether you need a custom scFv library screened against your specific target or a full phage display service from biopanning through to purified IgG, GNG’s expert team manages every step from VH/VL cloning and phagemid transfection to affinity maturation and final antibody characterization.
Diverse population gene pool across various disease background and healthy donors
DCloning of VH and VL in phagemid vector
Library preparation and transfection
Packaging and phage preparation
Biopanning against the target 4 round
ScFv generation and sequencing of binders
Final IgC cloned and expressed in HEK
Cancer/Infectious proteins injected into mice for immune response
Cloning of VH and VL and library generation
Biopanning against target/disease and functional assay
Identification of ScFv and its genetic sequence
Final igG cloned and expressed in HEK/CHO
Application and validation
Scale up of Antibodies
| Steps | Description | Deliverables |
|---|---|---|
| Library screening and biopanning | Selection and screening of the naïve or immune library. 4-5 rounds of biopanning to enrich binders | Progress report |
| ELISA screening | Screening and validation by ELISA to identify binders with desired specificity and affinity | Progress report |
| DNA extraction and sequencing | Extraction and sequencing of DNA from identified binders | Report DNA sequences |
| Development of full IgG | Gene synthesis Cloning of gene into a proprietary vector Transfection of host cell, screening, scale up & purification | Purified IgG antibody |
| Affinity Maturation | Enhancing the affinity and specificity of your antibodies through our affinity maturation services, optimizing their performance for various applications. | High affinity antibody |
| Antibody Characterization | Epitope mapping to determine the specific antigen binding site Binding kinetics analysis to measure the strength of antibody-antigen binding | Characterization report |
What Is CAR-T Therapy?
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary personalized immunotherapy in which a patient’s own T-cells are genetically modified to express synthetic receptors that recognize and destroy cancer cells. This next-generation treatment offers remarkable remission potential for hematological malignancies including B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and multiple myeloma, and is rapidly expanding into solid tumor indications.
GeNext Genomics delivers high-affinity antibodies and scFv fragments essential for CAR construct design enabling next-generation CAR-T therapies that target cancer with precision and power.
Why scFv Quality Matters
01. Target Recognition Accuracy: The scFv’s affinity and specificity directly determine how accurately the CAR-T cell identifies its cancer target and high-quality scFv means fewer missed targets and more effective cancer cell killing.
02. CAR Expression & Proper Folding: scFv sequence and structural characteristics impact how well the CAR construct expresses on the T-cell surface and maintains correct three-dimensional folding critical for functional CAR-T activity.
03. Off-Target Toxicity & Safety Profile: scFv specificity directly influences whether the CAR-T cells attack healthy tissues engineering a highly specific scFv is the foundation of a safe, clinically viable CAR-T therapeutic.
Expertise
Our team consists of experts with extensive experience in phage display technology and antibody discovery.
Quality
We prioritize quality at every step of the process to deliver reliable and high-performance antibody candidates.
Customization
Tailored solutions designed to address your specific project requirements.
Timely Delivery
Efficient project management ensures timely delivery of results to meet your deadlines.
Connect with
GeNext Genomics
discuss your project requirements and receive a
customized quote.
GET IN TOUCH WITH US